Cancer Antigen 19-9
TumormarkerZuletzt geprüft: 7. April 2026. Quellenansatz: Standardkontext zur Laborinterpretation, allgemeine medizinische Referenzmaterialien sowie öffentliche Gesundheits- oder klinische Leitlinien, sofern relevant.
Was ist Cancer Antigen 19-9?
Cancer Antigen 19-9 (CA 19-9) is a carbohydrate antigen—specifically a sialylated Lewis-a blood group antigen—that is found on the surface of certain epithelial cells and shed into the bloodstream. It was originally identified using a monoclonal antibody (1116 NS 19-9) raised against a human colon carcinoma cell line. CA 19-9 is produced by normal pancreatic and biliary ductal cells, as well as gastric, colonic, endometrial, and salivary epithelium at low levels.
CA 19-9 is the most widely used serum biomarker for pancreatic adenocarcinoma. It serves primarily as a tool for monitoring treatment response, assessing surgical resectability, and detecting disease recurrence. CA 19-9 is not recommended as a screening test for pancreatic cancer in the general population due to insufficient sensitivity and specificity. Approximately 5–10% of the population lacks the Lewis antigen and cannot synthesize CA 19-9, making the test uninformative in these individuals regardless of disease status. Biliary obstruction from any cause can markedly elevate CA 19-9, reducing its specificity.
Warum der Wert wichtig ist
CA 19-9 is the most clinically useful serum marker for pancreatic ductal adenocarcinoma. Preoperative CA 19-9 levels help predict resectability—very high values (>1000 U/mL) often indicate unresectable or metastatic disease. Declining CA 19-9 after surgery or chemotherapy suggests treatment response, while rising levels signal disease progression or recurrence. Because CA 19-9 is also elevated in benign biliary obstruction, cholangitis, pancreatitis, and other gastrointestinal conditions, results must be interpreted alongside imaging and clinical findings.
Normale Referenzbereiche
| Gruppe | Bereich | Einheit |
|---|---|---|
| Adults | 0–37 | U/mL |
| Lewis antigen-negative individuals | Undetectable (test not applicable) | U/mL |
Referenzbereiche können je nach Labor variieren. Vergleichen Sie Ihre Ergebnisse immer mit den Bereichen Ihres Testlabors.
Was hohe CA 19-9-Werte bedeuten
Häufige Ursachen
- Pancreatic adenocarcinoma
- Cholangiocarcinoma (bile duct cancer)
- Biliary obstruction (benign or malignant)
- Acute and chronic pancreatitis
- Cholangitis
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Cystic fibrosis
- Liver cirrhosis
Mögliche Symptome
- Jaundice (yellowing of skin and eyes)
- Unexplained weight loss
- Abdominal or back pain
- New-onset diabetes in adults over 50
- Loss of appetite
- Dark urine and pale stools
- Nausea
Was zu tun ist: Elevated CA 19-9 requires imaging (typically CT or MRI of the abdomen) to identify the underlying cause. If biliary obstruction is present, CA 19-9 should be re-measured after biliary drainage, as obstruction alone can cause marked elevation. For patients with known pancreatic cancer, serial CA 19-9 is used to monitor chemotherapy response and detect recurrence. Levels >1000 U/mL preoperatively may indicate unresectable disease. Additional workup may include endoscopic ultrasound with biopsy and cross-sectional imaging.
Was niedrige CA 19-9-Werte bedeuten
Häufige Ursachen
- Normal physiological state
- Lewis antigen-negative phenotype (5–10% of population)
- Successful cancer treatment
Mögliche Symptome
- No symptoms associated with low CA 19-9
Was zu tun ist: Low or undetectable CA 19-9 is typically normal. In Lewis antigen-negative individuals, CA 19-9 will be undetectable regardless of disease status, and the test should not be used for monitoring. After cancer treatment, normalization of CA 19-9 is a favorable prognostic indicator, though continued surveillance with imaging remains essential.
Wann wird ein CA 19-9-Test empfohlen?
- Monitoring treatment response in pancreatic cancer
- Assessing surgical resectability of pancreatic tumors
- Surveillance for recurrence after pancreatic cancer surgery
- Helping differentiate malignant from benign pancreatic cysts
- Monitoring cholangiocarcinoma treatment
Häufig gestellte Fragen
Verwandte Biomarker
Quellen- und Prüfungsansatz
Biomarker-Glossarseiten sind erklärende Bildungsinhalte und sollten immer zusammen mit den Referenzbereichen und Kommentaren Ihres Labors sowie Ihrer Ärztin oder Ihres Arztes interpretiert werden. Mehr zu unseren redaktionellen Standards und unserem Prüfprozess finden Sie in unserer Redaktionsrichtlinie und Prüfprozess für Inhalte.
Möchten Sie Ihre CA 19-9-Werte analysieren lassen?
Laden Sie Ihre Laborwerte hoch und erhalten Sie sofort eine KI-gestützte Einordnung aller Biomarker.
Laborwerte hochladen →Medizinischer Hinweis: Diese Informationen dienen nur Bildungszwecken und ersetzen keine professionelle medizinische Beratung, Diagnose oder Behandlung. Referenzbereiche können zwischen Laboren variieren. Besprechen Sie die Interpretation Ihrer konkreten Testergebnisse immer mit Ihrer medizinischen Fachperson.